Swiss National Bank Increases Stake in DexCom, Inc. (DXCM)

Swiss National Bank lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 307,900 shares of the medical device company’s stock after acquiring an additional 8,400 shares during the period. Swiss National Bank owned 0.36% of DexCom worth $22,523,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Independent Portfolio Consultants Inc. grew its position in shares of DexCom by 0.4% during the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after acquiring an additional 9 shares during the last quarter. Bbva Compass Bancshares Inc. grew its position in shares of DexCom by 1.9% during the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock worth $268,000 after acquiring an additional 69 shares during the last quarter. Public Employees Retirement Association of Colorado grew its position in shares of DexCom by 0.4% during the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock worth $1,362,000 after acquiring an additional 83 shares during the last quarter. King Luther Capital Management Corp grew its position in shares of DexCom by 0.7% during the first quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock worth $1,026,000 after acquiring an additional 90 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its position in shares of DexCom by 0.8% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 18,077 shares of the medical device company’s stock worth $1,532,000 after acquiring an additional 140 shares during the last quarter.

DXCM has been the topic of a number of research reports. Canaccord Genuity restated a “buy” rating and set a $90.00 target price on shares of DexCom in a research report on Wednesday, June 7th. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Cowen and Company restated a “buy” rating and set a $90.00 target price on shares of DexCom in a research report on Friday, July 14th. BMO Capital Markets restated a “buy” rating and set a $105.00 target price on shares of DexCom in a research report on Thursday, July 13th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $78.00 target price on shares of DexCom in a research report on Wednesday, July 12th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. DexCom presently has a consensus rating of “Buy” and a consensus target price of $87.64.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://sportsperspectives.com/2017/09/11/swiss-national-bank-increases-stake-in-dexcom-inc-dxcm.html.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at 71.26 on Monday. DexCom, Inc. has a 12-month low of $57.68 and a 12-month high of $95.40. The firm has a 50-day moving average price of $71.90 and a 200-day moving average price of $74.32. The firm’s market cap is $6.17 billion.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to the consensus estimate of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The firm’s revenue was up 24.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.24) EPS. On average, equities research analysts expect that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.

In other news, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $71.86, for a total value of $431,160.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,979 shares of company stock valued at $1,646,805. 1.70% of the stock is owned by company insiders.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply